Strides Shasun’s subsidiary, Strides Pharma Global, Singapore has received tentative approval from the United States Food & Drug Administration (USFDA) for its Para IV filing of Fingolimod Capsules, 0.5 mg. The product can be launched on generic market formation expected in February 2019, with a potential 180 day exclusivity.
Fingolimod Capsules is used for treatment of adult patients with relapsing forms of multiple sclerosis. The product is currently sold by Novartis under the brand name GILENYA. According to IMS data, the US market for Fingolimod Capsules is around $2 billion. Fingolimod Capsules registered a healthy CAGR of 10 % over last 5 years as per IMS December 2016 MAT data.
Strides Shasun (formerly known as Strides Arcolab) is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.20 |
| Dr. Reddys Lab | 1322.95 |
| Cipla | 1309.90 |
| Zydus Lifesciences | 891.65 |
| Lupin | 2303.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: